Should I buy Protagonist Therapeutics, Inc. (PTGX) stock or is it too late?
No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.
Firm-by-firm track record on Protagonist Therapeutics, Inc.
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| JP Morgan | 86 % | +69.0 % | 7 | $106 -29% |
| HC Wainwright & Co. | 87 % | +64.3 % | 31 | $117 -22% |
| JMP Securities | 71 % | +40.9 % | 14 | $69 -54% |
| BMO Capital | 62 % | +14.5 % | 8 | $178 +19% |
| SVB Leerink | 33 % | +13.3 % | 6 | — |
✅ Reasons to believe
- 100% of analysts rate it a buy (Buy consensus, 10 ratings) — a sign of market conviction.
- Median price target $162, i.e. +8% from the current price ($150).
- The most reliable firm on PTGX, Wedbush (100% hit rate, 2 scored calls), targets $173 (call made on August 10, 2026, maturing on August 10, 2027) (+16%) in its most recent call, and $86 (call made on October 28, 2025, maturing on October 28, 2026) (-42%) in the one coming due soonest.
⚠️ Reasons to hesitate
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
- A near-unanimous consensus leaves little room for positive surprise — a lot of optimism is already baked in.
The analyst consensus on PTGX
Median target $162 (+8%) · 10 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Protagonist Therapeutics, Inc. now?
We won't decide for you. The facts: 100% of analysts rate it a buy, median target $162 (+8%), and Wedbush (most reliable on PTGX, 100%) targets $173. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Protagonist Therapeutics, Inc.?
Not according to analysts: the median target ($162) is still +8% above the current price ($150) (most reliable on PTGX: Wedbush, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Protagonist Therapeutics, Inc. still worth investing in?
It depends on the gap between the price ($150) and its estimated value: analysts target $162 on median (+8%), with 100% buys (most reliable on PTGX: Wedbush, 100%). Cross-check with their real reliability on PTGX and the cautions above. Information, not advice.
What's the main risk in buying PTGX?
A 12-month target is not a guaranteed path: the price can fall in the meantime.
→ Go deeper: the full Protagonist Therapeutics, Inc. profile (consensus, analyst reliability, price target, performance).